US-Listed Biological Products, (No Diagnostic Substances) — Operating Income Percentiles
Population: 152 US-listed companies (SIC 2836), most recent complete fiscal year per filer; fiscal year ends 2025-06-30 to 2026-06-30.
| 10th percentile | $-302.7M |
|---|
| 25th percentile | $-148.0M |
|---|
| Median | $-55.6M |
|---|
| 75th percentile | $-9.1M |
|---|
| 90th percentile | $12.5M |
|---|
| Mean | $19.8M |
|---|
| Minimum | $-3.1B |
|---|
| Maximum | $10.0B |
|---|
Methodology & sources
Operating Income as filed in the most recent complete fiscal year per company (period > 300 days, fiscal year end within the last 18 months); percentiles computed in the database via percentile_cont, never by a model.
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, as of 2026-06-30.
Scope: {"source": "SEC EDGAR: api.mv_sic x api.v_company_financials (as-filed)", "selection": "je Firma das jüngste volle Geschäftsjahr (>300 Tage, Ende in den letzten 18 Monaten); Umsatzband filtert über de
Evidence samples
Query this live via API/MCP (template peer_percentiles); terms: /nutzung. Cite as: FACTANKER, https://factanker.com/industries/sic-2836/operating-income